Dermatology News

The National Psoriasis Foundation’s medical board strongly recommends dietary weight loss with a hypocaloric diet for overweight and obese patients with psoriasis, and weakly suggests that overweight or obese patients with psoriatic arthritis both supplement their diet with vitamin D and lose weight.

Patients with severe atopic eczema that was predominately active had increased risk for CV outcomes, according to a study published in The BMJ.

More than 30% of patients with rheumatoid arthritis, psoriatic arthritis or psoriasis either switched or discontinued their diseasemodifying antirheumatic drug treatment following a cardiovascular event, according to findings published in Arthritis Care and Research.

Atopic dermatitis in children and adults can improve with the treatment of a solution containing Roseomonas mucosa, which decreases the severity of the disease and reduces the rate of Staphylococcus aureus colonization in children, according to findings from a phase 1 and 2 trial.

DESTIN, Fla. — Rheumatologists should collaborate more closely with dermatologists to recognize and diagnose early cases of psoriatic arthritis, according to Arthur Kavanaugh, MD, a professor of medicine and director of the Center for Innovative Therapy at the University of California, San Diego.

The FDA has approved rituximab for the treatment of adult patients with moderate-to-severe pemphigus vulgaris, a rare autoimmune blistering disease that affects the skin and mucous membranes, according to a company press release.

A combination of physician’s global assessment and body surface area can be used as an alternative to the Psoriasis Area and Severity Index for measuring disease activity in patients with psoriatic arthritis who have been treated with certolizumab pegol, according to findings published in the Journal of Rheumatology.

Hemangeol was found to have a good overall safety profile as treatment for healthy children with infantile hemangioma, according to a study using a nationwide claims database in France.

The FDA has approved a label extension for UCB’s TNF inhibitor Cimzia to include an indication for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, according to a company press release.

Patients classified as high users of hydrochlorothiazide had a higher risk for melanoma, according to findings published in JAMA Internal Medicine.